论文部分内容阅读
目的 :评价依托泊苷低剂量持续口服治疗晚期非小细胞肺癌的临床效果。方法 :对 2 2例晚期非小细胞肺癌病人采用依托泊苷软胶囊口服 ,剂量按 5 0mg·m- 2 ·d- 1计算 ,实际剂量 (46±s3)mg·m- 2 ·d- 1,晨起空腹一次顿服 ,连服 2 1d ,每 2 8～ 35d为一个周期。按WHO实体瘤疗效评价标准及毒副作用标准确定疗效及毒副作用。结果 :病人接受(2 .9± 0 .9)个周期化疗后 ,部分缓解占 2 3% (5 /2 2 ) ,稳定占 36 % (8/ 2 2 ) ,进展为 4 1% (9/ 2 2 )。毒副作用轻微。结论 :依托泊苷软胶囊低剂量持续口服对晚期非小细胞肺癌病人获得较好的疗效 ,毒副作用轻微 ,易为病人接受
Objective: To evaluate the clinical efficacy of low dose etoposide sustained oral treatment of advanced non-small cell lung cancer. Methods: Twenty-two patients with advanced non-small cell lung cancer were treated with etoposide soft capsules orally. The dose was 50 mg · m-2 · d-1. The actual dose (46 ± s3) mg · m-2 · d-1 , Morning fasting once Dayton clothing, and even served 2 1d, every 2 8 ~ 35d for a cycle. According to WHO solid tumor efficacy evaluation criteria and toxic side effects to determine the efficacy and side effects. Results: After the patients received chemotherapy (2.9 ± 0.9) cycles, the partial response rate was 23% (5/2 2), stable rate was 36% (8/2 2), and the progression rate was 41% (9 / twenty two ). Toxic side effects. Conclusion: Etoposide soft capsule low-dose continuous oral administration of advanced non-small cell lung cancer patients get better efficacy, minor side effects, easy for patients to accept